Sanofi: FDA approves fexinidazole for sleeping sickness
(CercleFinance.com) - The US Food and Drug Administration (FDA) has approved fexinidazole as the first all-oral treatment for Trypanosoma brucei gambiense (human African trypanosomiasis) sleeping sickness.
Fexinidazole has been developed in partnership with the national sleeping sickness programs of the Democratic Republic of Congo (DRC) and the Central African Republic (CAR), and Sanofi.
Sleeping sickness is a parasitic disease transmitted by the bite of an infected tsetse fly. It mainly affects people living in remote rural areas of sub-Saharan Africa, where an estimated 65 million people are at risk of infection.
Current treatment options for the disease are effective, but burdensome for patients and health workers due to the need for infusion or injection, requiring hospitalisation, which is particularly difficult for people living in remote areas, it said.
Copyright (c) 2021 CercleFinance.com. All rights reserved.